Maximize Every Sample: How Evercode v4 Redefines Performance in Whole Transcriptome Profiling
Published: 24 Mar 2026
Author: Precedence Research
Parse Biosciences, a part of QIAGEN known as the leading provider of scalable and accessible single-cell sequencing solutions, has launched the new Evercode™ Whole Transcriptome v4 product line today. This new product improves scalability, boosts sensitivity, and streamlines the workflow for single-cell RNA sequencing.
Precision at Scale: Parse Biosciences Unveils v4 Chemistry with Unmatched Gene Sensitivity
The Evercode v4 system features impressive scalability, supporting up to five million cells and 384 samples in one run. This allows researchers to perform large studies while maintaining sample resolution. The enhanced chemistry improves gene detection per cell and reduces the number of sequencing reads needed, which helps lower overall sequencing costs.
According to Precedence Research, the Specimen Retrieval Market size accounted for USD 316.22 billion in 2025 and is predicted to increase from USD 330.86 billion in 2026 to approximately USD 497.22 billion by 2035, expanding at a CAGR of 4.63% from 2026 to 2035 as demand grows for adoption of minimally invasive surgery, focus on patient safety and infection control and growing prevalence of chronic diseases.
A new magnetic bead-based workflow has been introduced, replacing the traditional centrifugation steps and improving cell recovery by up to 75%. This innovation allows researchers to gather more data from limited or precious samples. The optimized process reduces hands-on time and the number of pipetting steps, and is designed to support laboratory automation, making it suitable for labs with different levels of experience in single-cell techniques.
Capture Every Detail: Enhanced Retrieval for Rare Cell Discovery in Evercode v4
Additionally, Evercode v4 effectively removes off-target reads, which improves gene detection per cell, even at lower sequencing depths and costs compared to other options. With its high sensitivity, Evercode v4 offers better biological resolution for researchers studying rare cell types or genes with low expression levels.
The chemistry behind Evercode Whole Transcriptome v4 is present across the entire Evercode Whole Transcriptome product range, which features Evercode Fixation and experiments carried out in Parse’s GigaLab.
"From the beginning, our goal has been to provide the research community with single-cell technology that is scalable, accessible, and high-performing," said Charlie Roco, PhD, Co-founder and Chief Technology Officer of Parse Biosciences. "Evercode v4 reflects years of development and direct feedback from our users, marking a major improvement in cell recovery and sensitivity, along with a simpler workflow.
A recent report by Precedence Research highlights that the Specimen Retrieval Market is benefiting from technological advancements in robotic-assisted devices, growing demand for patient safety and infection control, and increasing healthcare infrastructure investments in emerging markets.